Meet
Emily Donaldson

Principal

Emily Donaldson provides strategic advice and policy analysis to a wide range of clients across the healthcare industry.

Before joining Avalere, Emily served as director of US Policy at AbbVie, where she developed policies and strategies to help the business navigate the private health insurance and Medicaid markets, the 340B program, and the state health policy landscape. Previously, she served as deputy vice president for the Policy and Research department at PhRMA, where she led the commercial market and state issues portfolios. She has also served as director of state policy at the Blue Cross Blue Shield Association, policy counsel for BlueCross BlueShield of South Carolina, and staff counsel for the South Carolina Senate’s Office of Senate Research.

Emily holds a JD from the University of South Carolina and a BFA from Columbia College.

Authored Content


HRSA 2023 340B purchase data demonstrates continued program growth and that sales for the top 10 340B drugs exceeded sales for those drugs in Medicare.

In preparation for the 2024 state legislative sessions, stakeholders should consider how states will continue to shape the 340B policy landscape.

Some federal grant recipients use 340B program eligibility to expand their reach and services provided to a wide range of patient populations.

Key 340B stakeholders include the federal government, patients, pharmacies, drug manufacturers, PBMs, plans, and the 340B prime vendor.

Section 340B of the Public Health Service Act requires significant discounts on outpatient drugs for “covered entities"—safety-net providers and programs.

The SCOTUS decision is the most prominent action related to the 340B program, but ongoing litigation among stakeholders and growing activity at the state level are catalyzing developments that could shape the 340B landscape